Strongbridge Biopharma plc(NASDAQ:SBBP) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 27, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.73.
Strongbridge Biopharma plc (SBBP) remained unchanged at the close of Friday session. Even as the volume increased to 25,039 ,the shares failed to make any impression and ended at 0 points or 0.00% at $4. The trading session commenced at $3.95 and the stock hit a high of $4 and touched $3.8 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $6.3899 and the 52-week low is $2. The company has a market cap of $141 M and has approximately 3,53,35,026 outstanding shares.
Strongbridge Biopharma plc is a biopharmaceutical company focused on the development in-licensing acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The Companys primary focus has been to build its franchise around rare endocrine disorders which includes product candidates for the treatment of endogenous Cushings syndrome and acromegaly two rare diseases with a high unmet need for treatment options. The Company intends to use a small focused sales force to market its products if approved in the United States European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.